Media Articles Related to Micardis HCT (Telmisartan / Hydrochlorothiazide)
Source: MedicineNet Chronic Obstructive Pulmonary Disease (COPD) Specialty [2013.11.25]
Title: Pulmonary Hypertension
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 11/25/2013 12:00:00 AM
Increased risk of alcohol-related hypertension in individuals who flush after drinking
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2013.11.21]
Excessive drinking is a known risk factor for hypertension. Drinking that results in facial flushing indicates high sensitivity or even intolerance to alcohol. A study of the relationship between drinking and these two conditions has found that drinking-related hypertension has a lower threshold value and higher risk in flushers than in non-flushers.
Some allergy suffers with hypertension may be at increased risk for severe reaction
Source: Allergy News From Medical News Today [2013.11.12]
Oral allergy syndrome sufferers that take high blood pressure medications may experience extreme facial swelling and difficulty breathing the next time they bite into a juicy apple.
In low-income urban neighborhoods the rates of diabetes, hypertension, heart disease and stroke are much higher
Source: Hypertension News From Medical News Today [2013.11.07]
There is more to the cost of living in a food desert than higher prices for the few fruits and vegetables sold nearby, according to a study by an Indiana University-Purdue University Indianapolis researcher and the Marion County Public Health Department.
Further positive Opsumit (macitentan) data in pulmonary arterial hypertension presented at CHEST 2013
Source: Hypertension News From Medical News Today [2013.10.31]
Actelion (SIX: ATLN) has announced that following the recent FDA approval and positive CHMP opinion for macitentan (Opsumit®) in pulmonary arterial hypertension (PAH), further positive data on the efficacy of macitentan from the SERAPHIN study were presented at CHEST 2013 in Chicago, USA (26-31 October 2013).
Published Studies Related to Micardis HCT (Telmisartan / Hydrochlorothiazide)
Comparison of therapies between fixed-dose telmisartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild to moderate hypertension. [2009.01]
Among angiotensin receptor blockers (ARBs), telmisartan is suggested to function as a partial agonist of peroxisome proliferator-activated receptor-gamma (PPAR gamma) and to improve lipid and glucose metabolism. Clinical benefits of telmisartan over other ARBs may be apparent in combination with diuretics, which have harmful influences on lipid and glucose metabolism...
The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. [2008.06]
BACKGROUND: To compare the tolerability and safety of telmisartan +/- hydrochlorothiazide (HCTZ)... CONCLUSION: The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities.
Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. [2008.02]
In 2004-2005, the antihypertensive effects of telmisartan 80 mg versus valsartan 160 mg combined with hydrochlorothiazide 25 mg were assessed in a large placebo-controlled trial in patients with stages 1 and 2 hypertension and demonstrated that both agents were highly effective in lowering blood pressure (BP) compared with placebo and that telmisartan lowered BP significantly greater than valsartan...
Nilotinib is an orally administered BCR-ABL tyrosine kinase inhibitor that has shown good clinical efficacy in imatinib-resistant or -intolerant, Philadelphia chromosome-positive, chronic myeloid leukaemia (CML) in a phase I/II trial. The phase I component of the trial established the dosage regimen used in the phase II part of the trial, which included several arms...
Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. [2006.03]
The aim of this study was to compare the effects of telmisartan/hydrochlorothiazide (HCTZ) vs lisinopril/HCTZ combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. A total of 160 patients, 76 men and 84 women, aged 61-75 years, with sitting diastolic blood pressure (DBP)>90 mmHg and <110 mmHg and systolic blood pressure (SBP)>140 mmHg were randomized to receive temisartan 80 mg/HCTZ 12.5 mg o.d...
Clinical Trials Related to Micardis HCT (Telmisartan / Hydrochlorothiazide)
Telmisartan80mg/hydrochlothiazide12.5mg (Micardis Plus) ABPM Study in China [Completed]
to evaluate the trough and peak effect of once daily MICARDIS PLUS? (Telmisartan 80mg /
hydrochlorot hiazide 12. 5 mg) by 24 ABPM in patients with mild to moderate essential
INNOVATION Study - Telmisartan (Micardis?) in Incipient Diabetic Nephropathy [Completed]
The aim of this study is to compare the preventive effect of Telmisartan (Micardis?) versus
placebo control on the transition to overt nephropathy in patients with diabetic nephropathy
manifesting mic roalbuminuria associated with type II diabetes, and to evaluate the efficacy
and safety of Telmisart an (Micardis?, Gliosartan?, Kinzal?, Kinzalmono?, Predxal?, Pritor?,
Samertan?, Telmisartan?) for di abetic nephropathy patients.
PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg [Recruiting]
PRO-POWER is an observational cohort study for a period of 24 weeks. All recruited patients
will have essential hypertension. In addition, the patients will have at least one other
contributing risk factor for cardiovascular events. The study aims to evaluate the safety,
efficacy and protection of Micardis 80mg/Micardis plus 80/12. 5mg from cardiovascular risks
in patients with essential hypertension
CKD-828 Telmisartan Non-Responder Trial [Recruiting]
The aim of the present study is to evaluate the efficacy and safety of two dose combination
of Telmisartan/S-Amlodipine (40/2. 5mg and 40/5mg) compared with telmisartan monotherapy
(80mg) in hypertensive patients inadequately controlled by telmisartan monotherapy.
Telmisartan80/HCTZ25 Versus telmisartan80/HCTZ12.5 in Hypertension Not Responding to telmisartan80/HCTZ12.5 [Completed]
The primary objective of this trial is to demonstrate that a fixed dose combination of
telmisartan 8 0 mg plus hydrochlorothiazide 25 mg (T80/H25) is superior in reducing blood
pressure after eight wee ks compared with a fixed dose combination of telmisartan 80 mg plus
hydrochlorothiazide 12. 5 mg (T80
/H12. 5) in patients who fail to respond to six weeks treatment with T80/H12. 5.
Reports of Suspected Micardis HCT (Telmisartan / Hydrochlorothiazide) Side Effects
Blood Pressure Increased (9),
Renal Failure Acute (7),
Drug Ineffective (6),
Injection Site Haemorrhage (6),
Rales (6), more >>